UBS Group’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-12
| Closed | -$92 | – | 10824 |
|
|
2026
Q1 | $92 | Sell |
12
-28
| -70% | -$263 | ﹤0.01% | 10131 |
|
|
2025
Q4 | $356 | Buy |
40
+27
| +208% | +$477 | ﹤0.01% | 10009 |
|
|
2025
Q3 | $378 | Buy |
13
+6
| +86% | +$129 | ﹤0.01% | 9709 |
|
|
2025
Q2 | $98 | Sell |
7
-102
| -94% | -$1.12K | ﹤0.01% | 10008 |
|
|
2025
Q1 | $853 | Sell |
109
-712
| -87% | -$6.33K | ﹤0.01% | 9640 |
|
|
2024
Q4 | $6.28K | Buy |
821
+593
| +260% | +$13.5K | ﹤0.01% | 8572 |
|
|
2024
Q3 | $12.1K | Buy |
+228
| New | +$21.8K | ﹤0.01% | 7647 |
|
|
2024
Q2 | – | Sell |
-60
| Closed | -$12.2K | – | 9904 |
|
|
2024
Q1 | $12.2K | Buy |
+60
| New | +$10.7K | ﹤0.01% | 7149 |
|
|
2023
Q3 | – | Sell |
-19
| Closed | -$5.15K | – | 9794 |
|
|
2023
Q2 | $5.15K | Buy |
+19
| New | +$6.64K | ﹤0.01% | 7469 |
|
|
2023
Q1 | – | Sell |
-16
| Closed | -$5.93K | – | 10080 |
|
|
2022
Q4 | $5.93K | Buy |
+16
| New | +$7.98K | ﹤0.01% | 9108 |
|
|
2021
Q4 | – | Sell |
-14
| Closed | -$13K | – | 10535 |
|
|
2021
Q3 | $13K | Buy |
14
+11
| +367% | +$7.12K | ﹤0.01% | 7672 |
|
|
2021
Q2 | $2K | Sell |
3
-20
| -87% | -$12.9K | ﹤0.01% | 8963 |
|
|
2021
Q1 | $18K | Buy |
23
+21
| +1,050% | +$21.1K | ﹤0.01% | 7467 |
|
|
2020
Q4 | $2K | Sell |
2
-189
| -99% | -$131K | ﹤0.01% | 8105 |
|
|
2020
Q3 | $110K | Buy |
191
+44
| +30% | +$26.2K | ﹤0.01% | 5126 |
|
|
2020
Q2 | $85K | Buy |
147
+136
| +1,236% | +$78.2K | ﹤0.01% | 5427 |
|
|
2020
Q1 | $5K | Buy |
11
+6
| +120% | +$5.43K | ﹤0.01% | 7302 |
|
|
2019
Q4 | $8K | Buy |
+5
| New | +$4.35K | ﹤0.01% | 7392 |
|
|
2019
Q2 | – | Sell |
-14
| Closed | -$12K | – | 8048 |
|
|
2019
Q1 | $12K | Sell |
14
-17
| -55% | -$13.7K | ﹤0.01% | 6687 |
|
|
2018
Q4 | $14K | Buy |
+31
| New | +$18.2K | ﹤0.01% | 7043 |
|
|
2018
Q3 | – | Sell |
-6
| Closed | -$2K | – | 8150 |
|
|
2018
Q2 | $2K | Buy |
+6
| New | +$2.6K | ﹤0.01% | 7733 |
|
|
2018
Q1 | – | Sell |
-15
| Closed | -$13K | – | 8037 |
|
|
2017
Q4 | $13K | Buy |
15
+7
| +88% | +$6.75K | ﹤0.01% | 6868 |
|
|
2017
Q3 | $9K | Sell |
8
-44
| -85% | -$44.1K | ﹤0.01% | 6952 |
|
|
2017
Q2 | $66K | Buy |
52
+47
| +940% | +$94.6K | ﹤0.01% | 5463 |
|
|
2017
Q1 | $10K | Buy |
+5
| New | +$12.2K | ﹤0.01% | 6615 |
|
Other funds holding MTNB
HIW
SIG
UBS Group's MTNB Position: Q2 2026 in Review
UBS Group sold out of Matinas BioPharma (MTNB) in Q2 2026, closing a stake of 12 shares — an estimated $92 sold.
UBS Group first reported a position in MTNB in Q1 2017 and held it in 25 quarters. The position peaked at $110K in Q3 2020. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- UBS Group reported no remaining Matinas BioPharma position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 12 Matinas BioPharma shares in Q2 2026, an estimated $92.
- UBS Group first reported a position in Matinas BioPharma in Q1 2017 and held it in 25 quarters.
- UBS Group's Matinas BioPharma position peaked at $110K in Q3 2020.
- 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.